Lundbeck Milestone


Entered China in 1990s through partnership on Deanxit®



Launch of Cipramil® in 2002 and Lexapro® in 2006 through partnership

Commercial affiliate established in Beijing in 2007

Launch of Ebixa® through Lundbeck affiliate in 2007

Lundbeck Institute China chapter established in 2008 



Lexapro® co-promotion started from 2011

Launch of Chinese Neurology and Psychiatry Disease Week (CNPDW) in 2014

China becomes a strategic priority market for Lundbeck global  



The innovative solutions: Azilect® for PD and the antidepressant Brintellix® were approved by CFDA (China Food and Drug Administration) to serve more patients